State Ledger
Company profile

BridgeBio Oncology Therapeutics, Inc. CIK 1869105

Ticker
BBOT (Nasdaq)
Industry
Pharmaceutical Preparations
Headquarters
South San Francisco, CA 94080
Fiscal year end
2025 (FY)
Market Data
Close
$3.26
Change
-$0.06
Change %
-1.81%
Volume
16,990

BBOT · trading date Oct 12, 2026 · previous close $3.32 · source: Alpaca (IEX feed, not consolidated full-market data).

Key Financials
Revenue
—
Net income
-$134.04M
Total assets
$448.38M
Total liabilities
$37.29M
Stockholders' equity
$411.10M
Cash & equivalents
$373.69M
Operating income
-$145.82M
Operating cash flow
-$113.89M
Capital expenditures
$606.0K

Fiscal year 2025, via 10-K filed 2026-03-05. A dash means this figure wasn't reported in the source filing under a field State Ledger recognizes - not that the value is zero.

Financial Performance
Operating margin
—
Net margin
—
Free cash flow
-$114.50M
Free cash flow margin
—
Liabilities / assets
8.3%
Equity / assets
91.7%
CapEx / revenue
—
Operating cash flow / net income
0.85×

Derived from the fiscal year 2025 figures above. These metrics are mathematical calculations and do not represent a rating or assessment of the company.

Financial History
Fiscal yearRevenueNet incomeAssetsLiabilitiesEquity
2025 — -$134.04M $448.38M $37.29M $411.10M
2024 — -$74.28M $164.30M $19.58M -$178.64M
2023 — -$41.7K $332.9K $396.5K -$115.64M
Company Details
SIC code
2834
State of incorporation
DE
Active filer
Yes
Most recent SEC filing
Form 4
2026-09-14
Financials filed via
Form 10-K
filed 2026-03-05

"Most recent SEC filing" may differ from the filing used for the financial figures above.

Location
South San Francisco, CA 94080
256 E. GRAND AVENUE, SUITE 104
Data & Methodology

SEC EDGAR submissions API (identity, collected Sep 19, 2026, 15:11 UTC) and SEC XBRL Company Facts API (financials, collected Sep 26, 2026, 15:20 UTC) · figures as originally filed, not restated · a dash always means a value wasn't reported, never a real zero.

← Back to California — Public Companies